176 results
Page 2 of 9
8-K
EX-99.1
4b297i75eegi618s6v
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.1
ndvopv
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
hqadr
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
3hl65ac
30 May 23
Business combination disclosure
4:21pm
8-K
22u156mqc0 9cmmfe0
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
aizil4bll19nsye
22 May 23
Business combination disclosure
7:01am
8-K
3t3os0rpk70nk70c
22 May 23
Other Events
6:59am
8-K
EX-99.1
tbakb0 v2hnpxj
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
1lxymypoda7 2w2d8
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
iwzbhre
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-99.1
c3xo5kn2kgl q1k2
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
8-K
EX-10.1
ot029323
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
hicd5 ilqp667
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
upj 7nu252fi
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
d9byl0x7s409r
8 Nov 22
Regulation FD Disclosure
7:40am